Drug Trial Radar · NCT07625293
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Direct Biologics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying DB-3Q as a possible treatment for medically refractory Crohn's disease. The purpose of this study is to research and evaluate safety and effectiveness of the administration of bone marrow mesenchymal stem cell (bmMSC) derived extracellular vesicles product, DB-3Q, the study drug for Crohn's disease.
Conditions
- Crohn Disease (CD)
Interventions
DB-3QBiological
bmMSC derived, extracellular vesicle enriched secretome product
PlaceboOther
0.9% Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in SES-CD ScoreTime frame: 12 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University, St. Louis
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.